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Second neoplasms after cancers
of unknown primary
Even in populations with optimal structures for cancer
diagnosis and certification, 3%–5% of neoplasms are
classified as cancer of unknown primary (CUP) [1]. In the
Vaud Cancer Registry, they account for 2%–3% of all
neoplasms only [2].
CUPs tend to have poor prognosis and hence short
survival, i.e. 1-year survival was 15% in the Vaud Cancer
Registry [2]. Still, incidence of second primary cancers may
be increased after CUP. Thus, in the Swedish Family
Cancer Database, the standardized incidence ratio (SIR) of
subsequent cancer following a CUP was 1.69, and several
cancers had increased SIR, including skin and infection-related
cancer [1].
We consider in the present report data on selected
cancers following CUP using the Vaud Cancer Registry
dataset [2]. This includes incident cases of malignant
neoplasms in the Canton [3], whose population according to
the 2000 Census was 616 000 inhabitants. Passive and
active follow-up is recorded, and each subsequent item of
information concerning an already registered case is used to
complete the record of that patient. The present series
comprises a total of 2163 first CUP diagnosed from 1974 to
2007 and followed up to the end of 2007 for the occurrence
of a second primary cancer of any site and morphological
type [according to the standard International Classification
of Diseases for Oncology, 9th Edition (ICD-O-9), except
basal cell carcinoma of the skin], emigration or death, for
a total of 1872.7 person-years. Calculation of expected
numbers was based on site-, sex-, age- and calendar
year-specific incidence rates, multiplied by the
corresponding number of person-years at risk. The
significance of the observed/expected ratios (SIRs) and the
corresponding 95% confidence intervals (CIs) were based
on the Poisson distribution.
Overall, 43 second cancers were reported after CUP versus
29.9 expected, corresponding to a SIR of 1.4 (95% CI
1.0–1.9) (Table 1). Significant excess risks were observed for
cancer of the oral cavity and pharynx (eight observed, SIR
8.6, 95% CI 3.7–17.0). There were 8 squamous cell
carcinomas (SCCs) of the skin (SIR 2.1, 95% CI 0.9–4.2), 5
cancers of the prostate (SIR 1.1, 95% CI 0.4–2.6) and 22
other neoplasms (SIR 1.1, 95% CI 0.7–1.6).
Thus, the present data confirm, and further quantify, the
existence of excess cancer risk following CUP. Part of such
excess risk may be due to recurrences and diagnosis of primary
neoplasm, though the criteria for registration of second primary
neoplasms in the Vaud Cancer Registry were strict [4]. There is
also an increased medical surveillance after CUP diagnosis. This
may account, partly or largely, for the slight apparent excess risk
of prostate cancer restricted to the first year after CUP diagnosis
(SIR 1.8, based on three cases) since prostate cancer is strongly
influenced by prostate-specific antigen and other diagnostic
procedures [5–7]. This cannot explain, however, the excess risk
for other neoplasm: the SIR for all sites was 1.2 (95% CI 0.6–
2.0, based on 13 cases) during the first year after CUP, 1.3 (95%
CI 0.6–2.2, 13 cases) from 1 to 4 years and 2.0 (95% CI 1.2–3.2,
17 cases) ‡5 years after CUP diagnosis.
The excess risk for oral, pharyngeal and skin SCC are
however apparently greater than for other neoplasms. Since
some of these neoplasms are related to infectious agents
(human papillomavirus) [8–11], this supports the concept that
CUP-related (or treatment-induced) immunosuppression is
a relevant underlying mechanism [12, 13] of the excess cancer
risk after CUP. No cervical cancer was observed after CUP. This
can be explained, however, by adequate surveillance for cervical
cancer in this population [14].
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Table 1. Observed (O) and expected (E) number of second primary
cancers following 2163 first cancers of unknown primary site (Vaud,
Switzerland, 1974–2007)
Site of second primary O E SIR 95% CI
Oral cavity and pharynx 8 0.93 8.61 3.71–16.97
Skin, squamous cell
carcinoma
8 3.73 2.14 0.92–4.22
Prostate 5 4.51 1.11 0.36–2.59
Other sitesa 22 20.74 1.06 0.67–1.61
All sites 43 29.91 1.44 1.04–1.94
aInclude: one cancer of esophagus, liver, biliary tract, lung, skin melanoma,
male breast, endometrium, testis, bladder, thyroid and lymphoma; two
cancers of kidney; three cancers of stomach, colorectum, female breast.
SIR, standardized incidence ratio; CI, confidence interval.
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